Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.55 |
| ▸ | GLP1R | P43220 | 1/20 | 0.54 |
| ▸ | GCGR | P47871 | 1/20 | 0.54 |
| ▸ | GIPR | P48546 | 1/20 | 0.54 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.53 |
| ▸ | VIPR1 | P32241 | 2/20 | 0.53 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.52 |
| ▸ | TFPI | P10646 | 1/20 | 0.52 |
| ▸ | VIPR2 | P41587 | 2/20 | 0.50 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30880889 | 0.97 | BACE1 (0.54) | BACE1GLP1RGCGRGIPRKISS1R | |
| SCHEMBL31683306 | 0.92 | GLP1R (0.57) | BACE1GLP1RGCGRGIPRKISS1R | |
| SCHEMBL38664549 | 0.91 | GLP1R (0.52) | BACE1GLP1RGCGRGIPRKISS1R | |
| SCHEMBL31182625 | 0.91 | BACE1 (0.57) | BACE1GLP1RGCGRGIPRKISS1R | |
| SCHEMBL30906345 | 0.90 | BACE1 (0.65) | BACE1GLP1RGCGRGIPRVIPR1 | |
| SCHEMBL30903279 | 0.90 | BACE1 (0.62) | BACE1GLP1RGCGRGIPRKISS1R | |
| SCHEMBL31182918 | 0.89 | TFPI (0.64) | BACE1GLP1RGCGRGIPRVIPR1 | |
| SCHEMBL30320569 | 0.89 | BACE1 (0.58) | BACE1KISS1RVIPR1BACE2TFPI | |
| SCHEMBL29520890 | 0.89 | BACE1 (0.57) | BACE1KISS1RBACE2VIPR2 | |
| SCHEMBL30974430 | 0.89 | KISS1R (0.54) | BACE1KISS1RVIPR1BACE2TFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2026-03-10 | — | — | US | disclosed |
| US-20240092878-A1 | AN ANTIBODY FRAGMENT BASED ANTIFUNGAL CONJUGATE SELECTIVELY TARGETING CANDIDA | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2024-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | SERPINH1, HM13, NGLY1 | BACE1 99/4885GLP1R 2596/4885GCGR 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.